Related Experiment Video
Updated: Nov 25, 2025
Automated Cell Enrichment of Cytomegalovirus-specific T cells for Clinical Applications using the Cytokine-capture System
Published on: October 5, 2015
Case Report: Convalescent Plasma, a Targeted Therapy for Patients with CVID and Severe COVID-19
Karel F A Van Damme1,2, Simon Tavernier1,3, Nele Van Roy1
1Department of Internal Medicine and Pediatrics, Ghent University, Ghent, Belgium.
Abstract:
The disease course of COVID-19 in patients with immunodeficiencies is unclear, as well as the optimal therapeutic strategy. We report a case of a 37-year old male with common variable immunodeficiency disorder and a severe SARS-CoV-2 infection. After administration of convalescent plasma, the patient's condition improved rapidly. Despite clinical recovery, viral RNA remained detectable up to 60 days after onset of symptoms. We propose that convalescent plasma might be considered as a treatment option in patients with CVID and severe COVID-19. In addition, in patients with immunodeficiencies, a different clinical course is possible, with prolonged viral shedding.
